Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity

Pediatr Allergy Immunol. 2024 Aug;35(8):e14215. doi: 10.1111/pai.14215.

Authors

Paola Zangari¹, Carmela Giancotta¹, Lucia Pacillo¹, Nicole Colantoni², Fabrizio Leone², Donato Amodio^{1

2}, Veronica Santilli¹, Emma Concetta Manno¹, Nicola Cotugno^{1

2}, Beatrice Rivalta¹, Gioacchino Andrea Rotulo¹, Silvia Di Cesare², Andrea Diociaiuti³, May El Hachem³, Caterina Cancrini^{1

2}, Andrea Finocchi^{1

2}, Paolo Palma^{1

2}

Affiliations

¹ Clinical and Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
² Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
³ Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

PMID: 39105363
DOI: 10.1111/pai.14215

No abstract available

Keywords: atopic dermatitis; biologics; dupilumab; inborn errors of immunity.

Publication types

Letter

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Child, Preschool
Dermatitis, Atopic* / drug therapy
Dermatitis, Atopic* / immunology
Female
Humans
Infant
Male
Treatment Outcome
Young Adult

Substances

dupilumab
Antibodies, Monoclonal, Humanized

Grants and funding

Ministero della Salute